Cargando…
Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity
Serologic studies are crucial for clarifying dynamics of the coronavirus disease pandemic. Past work on serologic studies (e.g., during influenza pandemics) has made relevant contributions, but specific conditions of the current situation require adaptation. Although detection of antibodies to measu...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454079/ https://www.ncbi.nlm.nih.gov/pubmed/32544053 http://dx.doi.org/10.3201/eid2609.201840 |
_version_ | 1783575456411287552 |
---|---|
author | Clapham, Hannah Hay, James Routledge, Isobel Takahashi, Saki Choisy, Marc Cummings, Derek Grenfell, Bryan Metcalf, C. Jessica E. Mina, Michael Barraquer, Isabel Rodriguez Salje, Henrik Tam, Clarence C. |
author_facet | Clapham, Hannah Hay, James Routledge, Isobel Takahashi, Saki Choisy, Marc Cummings, Derek Grenfell, Bryan Metcalf, C. Jessica E. Mina, Michael Barraquer, Isabel Rodriguez Salje, Henrik Tam, Clarence C. |
author_sort | Clapham, Hannah |
collection | PubMed |
description | Serologic studies are crucial for clarifying dynamics of the coronavirus disease pandemic. Past work on serologic studies (e.g., during influenza pandemics) has made relevant contributions, but specific conditions of the current situation require adaptation. Although detection of antibodies to measure exposure, immunity, or both seems straightforward conceptually, numerous challenges exist in terms of sample collection, what the presence of antibodies actually means, and appropriate analysis and interpretation to account for test accuracy and sampling biases. Successful deployment of serologic studies depends on type and performance of serologic tests, population studied, use of adequate study designs, and appropriate analysis and interpretation of data. We highlight key questions that serologic studies can help answer at different times, review strengths and limitations of different assay types and study designs, and discuss methods for rapid sharing and analysis of serologic data to determine global transmission of severe acute respiratory syndrome coronavirus 2. |
format | Online Article Text |
id | pubmed-7454079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-74540792020-09-03 Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity Clapham, Hannah Hay, James Routledge, Isobel Takahashi, Saki Choisy, Marc Cummings, Derek Grenfell, Bryan Metcalf, C. Jessica E. Mina, Michael Barraquer, Isabel Rodriguez Salje, Henrik Tam, Clarence C. Emerg Infect Dis Perspective Serologic studies are crucial for clarifying dynamics of the coronavirus disease pandemic. Past work on serologic studies (e.g., during influenza pandemics) has made relevant contributions, but specific conditions of the current situation require adaptation. Although detection of antibodies to measure exposure, immunity, or both seems straightforward conceptually, numerous challenges exist in terms of sample collection, what the presence of antibodies actually means, and appropriate analysis and interpretation to account for test accuracy and sampling biases. Successful deployment of serologic studies depends on type and performance of serologic tests, population studied, use of adequate study designs, and appropriate analysis and interpretation of data. We highlight key questions that serologic studies can help answer at different times, review strengths and limitations of different assay types and study designs, and discuss methods for rapid sharing and analysis of serologic data to determine global transmission of severe acute respiratory syndrome coronavirus 2. Centers for Disease Control and Prevention 2020-09 /pmc/articles/PMC7454079/ /pubmed/32544053 http://dx.doi.org/10.3201/eid2609.201840 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Perspective Clapham, Hannah Hay, James Routledge, Isobel Takahashi, Saki Choisy, Marc Cummings, Derek Grenfell, Bryan Metcalf, C. Jessica E. Mina, Michael Barraquer, Isabel Rodriguez Salje, Henrik Tam, Clarence C. Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity |
title | Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity |
title_full | Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity |
title_fullStr | Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity |
title_full_unstemmed | Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity |
title_short | Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity |
title_sort | seroepidemiologic study designs for determining sars-cov-2 transmission and immunity |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454079/ https://www.ncbi.nlm.nih.gov/pubmed/32544053 http://dx.doi.org/10.3201/eid2609.201840 |
work_keys_str_mv | AT claphamhannah seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT hayjames seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT routledgeisobel seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT takahashisaki seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT choisymarc seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT cummingsderek seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT grenfellbryan seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT metcalfcjessicae seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT minamichael seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT barraquerisabelrodriguez seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT saljehenrik seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity AT tamclarencec seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity |